Last updated: 11/07/2018 19:02:23
A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects
Trial description: A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: P. T. Daley-Yates, C. Majer-Teboul A. Prieur P. Minini R. Bidault P. Maison-Blanche C. Funck Brentano., 708092 ([130241). Cardiovascular (CV) Pharmacodynamics (PD) and Pharmacokinetics (PK) of Salmeterol (SALM) Following Single and Repeated Dosing in Chronic Obstructive Pulmonary Disease (COPD) [5/16/2003]. 5/21/2003: P. T. Daley-Yates, C. Majer-Teboul A. Prieur P. Minini R. Bidault P. Maison-Blanche C. Funck Brentano., 6/5/2003. 99th International Conference of the American Thoracic Society; Seattle, WA; USA. 2003 May 16; c2003.
PT Daley-Yates, C Majer-Teboul, A Prieur, P Minini, R Bidault, P Maison-Blanche, C Funck-Brentano. Cardiovascular (CV) Pharmacodynamics (PD) And Pharmacokinetics (PK) Of Salmeterol (SALM) Following Single And Repeated Dosing In Chronic Obstructive Pulmonary Disease (COPD). Am J Resp Crit Care Med 2003; 167(7): A319
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
salmeterol
Collaborators
Not applicable
Study date(s)
May 2001 to October 2001
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-29-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website